Novartis says SMA gene therapy is cost-effective at $4-5 mln per patient
Swiss drugmaker Novartis, which is shifting into rare diseases, said on Monday it believes its new gene therapy for the deadly disease spinal muscular atrophy could be cost-effective to healthcare systems at $4 million to $5 million per patient.
Swiss drugmaker Novartis, which is shifting into rare diseases, said on Monday it believes its new gene therapy for the deadly disease spinal muscular atrophy could be cost-effective to healthcare systems at $4 million to $5 million per patient.
“Four million dollars is a significant amount of money, but we believe this is a cost-effective point,” Dave Lennon, president of AveXis, the U.S. gene therapy developer bought by Novartis this year for $8.7 billion, said on a call with investors.
“We’ve shown through other studies we are cost effective in the range of $4-$5 million,” Lennon said. “And ultimately, this is important context as we consider how we’re going to evaluate value for (the therapy called) AVXS-101.”
Novartis Chief Executive Vas Narasimhan added the Swiss company was not yet ready to comment on commercial pricing for the one-time therapy, with that to be determined in talks with insurers and government payers in the United States, Europe and Japan.
ارسال به دوستان